Related Experiment Video
Updated: May 16, 2025

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus
Xiaoke Dou1,2, Lei Zhao3, Jing Li2
1Department of Endocrinology and Metabolism, The First Hospital of China Medical University, Shenyang, China.
Background:
Diabetes mellitus (DM) is a metabolic disorder associated with cognitive impairment. Glucagon-like peptide-1 (GLP-1) and its receptor (GLP-1R) have shown neuroprotective effects.
Scope Of Review:
This review explores the impact of DM on cognitive function. Diabetes-related cognitive impairment is divided into three stages: diabetes-associated cognitive decrements, mild cognitive impairment (MCI), and dementia. GLP-1R agonists (GLP-1RAs) have many functions, such as neuroprotection, inhibiting infection, and metabolic regulation, and show good application prospects in improving cognitive function. The mechanisms of GLP-1RAs neuroprotection may be interconnected, warranting further investigation. Understanding these mechanisms could lead to targeted treatments for diabetes-related cognitive dysfunction.
Major Conclusions:
Therefore, this paper reviewed the regulatory effects of GLP-1 on cognitive dysfunction and its possible mechanism. Further research is required to fully explore the potential of GLP-1 and its analogs in this context.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Oral Hypoglycemic Agents: Biguanides and Glitazones

